-+ 0.00%
-+ 0.00%
-+ 0.00%

ALNYLAM PHARMACEUTICALS INC - AMYLOID REGRESSION IN 22% OF VUTRISIRAN-TREATED PATIENTS

Reuters·11/08/2025 21:58:21

Please log in to view news